Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes

Stopped early · Phase 4

Conditions studied: Diabetes Mellitus, Type 2

In brief

Beta-blockers are medications used to treat cardiovascular disease (CVD) symptoms, including high blood pressure and chest pain. People with diabetes who receive beta-blockers may experience adverse health effects, but the exact cause of why this happens remains unknown. This study will examine the genetic factors that may influence how atenolol, a beta-blocker medication, affects fat breakdown, blood sugar levels, and heart function in people with type 2 diabetes.

Key facts

Study ID

NCT00925119

Run by

University of Maryland, Baltimore

People needed

31

Starts

2009-12-01

Expected to finish

2014-05-01

Last updated by the study team

2019-09-26

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes
• Pre-Diabetes

You may not qualify if…

• Insulin therapy
• Treatment with any beta-blocker in the 30 days before study entry
• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Greater than first degree heart block
• Heart rate less than 60 bpm
• Systolic blood pressure less than 90 mm Hg
• Raynaud's phenomenon
• Known history of angina, heart attack, heart failure, coronary revascularization, or automatic implantable cardioverter defibrillators
• Pregnant
• Creatinine clearance less than 35 ml/min
• Hematologic dysfunction (white blood cell [WBC] count less than 3000 or hematocrit less than 28%)
• Allergy to amide anesthetics

Where it is running

• University of Maryland — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.